Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Breast Carcinoma In Situ

ClinicalTrials.gov lists 379 trials for Breast Carcinoma In Situ or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 16.

MeSH D000071960 Neoplasms Neoplasm C04 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 33 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 87 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 28 Phase 4 Phase 4 4 Not applicable Not applicable 134 Observational Observational 83 Phase 1 Phase 1 33 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 87 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 28 Phase 4 Phase 4 4 Not applicable Not applicable 134 Observational Observational 83

Trials per phase (log scale)

189 of the 379 trials are tagged with Breast Carcinoma In Situ itself; the rest are tagged with a narrower condition beneath it.

Get the Breast Carcinoma In Situ report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Breast Carcinoma In Situ trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 21

1991: 1 trials (Observational 1) 1995: 1 trials (Phase 2 1) 1996: 1 trials (Observational 1) 1997: 3 trials (Phase 3 2, Phase 2 1) 1998: 2 trials (Observational 1, Phase 3 1) 1999: 2 trials (Phase 3 1, Phase 1 1) 2000: 3 trials (Phase 3 1, Phase 2 1, Phase 1 1) 2001: 2 trials (Observational 1, Not applicable 1) 2002: 6 trials (Phase 2 5, Phase 1/2 1) 2003: 9 trials (Observational 1, Not applicable 3, Phase 3 3, Phase 2 2) 2004: 10 trials (Observational 2, Not applicable 3, Phase 2 5) 2005: 13 trials (Observational 4, Not applicable 4, Phase 3 1, Phase 2 1, Phase 1 3) 2006: 13 trials (Observational 3, Not applicable 6, Phase 2 4) 2007: 14 trials (Observational 4, Not applicable 7, Phase 3 2, Phase 1 1) 2008: 21 trials (Observational 6, Not applicable 7, Phase 4 1, Phase 3 3, Phase 2 2, Phase 1 2) 2009: 20 trials (Observational 7, Not applicable 5, Phase 3 1, Phase 2 4, Phase 1/2 2, Phase 1 1) 2010: 15 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1 4) 2011: 13 trials (Observational 2, Not applicable 4, Phase 3 3, Phase 2 3, Phase 1/2 1) 2012: 8 trials (Observational 1, Not applicable 5, Phase 2 2) 2013: 10 trials (Observational 2, Not applicable 4, Phase 2 3, Phase 1 1) 2014: 11 trials (Observational 3, Not applicable 6, Phase 2 1, Phase 1/2 1) 2015: 16 trials (Observational 1, Not applicable 6, Phase 3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2016: 17 trials (Observational 5, Not applicable 6, Phase 3 2, Phase 2 3, Phase 1 1) 2017: 18 trials (Observational 2, Not applicable 10, Phase 3 1, Phase 2/3 1, Phase 2 4) 2018: 16 trials (Observational 7, Not applicable 2, Phase 4 1, Phase 2 3, Phase 1 3) 2019: 20 trials (Observational 3, Not applicable 8, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 4) 2020: 17 trials (Observational 3, Not applicable 7, Phase 3 1, Phase 2 3, Phase 1 3) 2021: 17 trials (Observational 2, Not applicable 11, Phase 2/3 1, Phase 2 3) 2022: 15 trials (Observational 6, Not applicable 4, Phase 2 3, Phase 1 2) 2023: 16 trials (Observational 6, Not applicable 4, Phase 2 5, Phase 1/2 1) 2024: 16 trials (Observational 3, Not applicable 5, Phase 2 7, Phase 1 1) 2025: 17 trials (Observational 1, Not applicable 8, Phase 4 1, Phase 3 1, Phase 2 5, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 12
2025 17
2024 16
2023 16
2022 15
2021 17
2020 17
2019 20
2018 16
2017 18

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 15 trials starting in 2026 and about 16 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 37 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 246 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Breast Carcinoma In Situ trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 33
Phase 1/2 8
Phase 2 87
Phase 2/3 2
Phase 3 28
Phase 4 4
Not applicable 134
Observational 83

How many Breast Carcinoma In Situ trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 9
Recruiting 55
Enrolling by invitation 1
Active, not recruiting 42
Completed 190

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Breast Carcinoma In Situ trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 16

Which drugs are being tested for Breast Carcinoma In Situ? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Anastrozole 11
Exemestane 6

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tamoxifen Pill 30
Radiation Therapy 14
Adjuvant Therapy 12
Letrozol (Femara, Novartis) 11
Best Practice (which may include intravenous Alteplase) 7

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Breast Carcinoma In Situ trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Thromboembolic event 28 4
Myocardial infarction 26 4
Osteoarthritis 26 1
Death 24 1
Ankle fracture 22 2

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Breast Carcinoma In Situ? (17)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Re-examining content validity of the BREAST-Q more than a decade later to determine relevance and comprehensiveness. Journal of patient-reported outcomes 2023 Yes
Evidence-Based Pragmatic Approach to the Management of Borderline or High-Risk Breast Lesions. AJR. American journal of roentgenology 2022 Yes
Strategies to Identify and Recruit Women at High Risk for Breast Cancer to a Randomized Controlled Trial of Web-based Decision Support Tools. Cancer prevention research (Philadelphia, Pa.) 2022 Yes
Improving well-being for individuals with persistent pain after surgery for breast cancer, lobular carcinoma in situ, or ductal carcinoma in situ: A randomized clinical trial. Contemporary clinical trials 2022 Yes
Increasing socioeconomically disadvantaged patients' engagement in breast cancer surgery decision-making through a shared decision-making intervention (A231701CD): protocol for a cluster randomised clinical trial. BMJ open 2022 Yes

Showing 5 of 17 publications.

Start your 14-day trial Email me all 17 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages